| A Trial Evaluating Two Imetelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (MDS) | Motesanib | Phase 4 | Not yet recruiting | Geron Corporation | 2026-11-16 |
| Zemetostat With Anlotinib in Patients With Recurrent/Metastatic Head and Neck Soft Tissue Sarcoma | Catequentinib | Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 2026-11-05 |
| Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver Metastases | Sunitinib | — | Enrolling by invitation | Chiyi Chen | 2026-11-03 |
| Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT | Motesanib | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 2026-11-02 |
| Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal Carcinoma | Catequentinib | Phase 2 | Not yet recruiting | Sun Yat-sen University | 2026-10-29 |
| Pucotenlimab and Anlotinib in Combination With Chemotherapy | Catequentinib | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 2026-10-27 |
| Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC | Famitinib | Phase 2 | Not yet recruiting | Ruijin Hospital | 2026-10-22 |
| A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | Imatinib | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-10-21 |
| MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC | Catequentinib | Phase 2 | Not yet recruiting | Peking University People's Hospital | 2026-10-21 |
| Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell Carcinoma | Sunitinib, Catequentinib | Phase 3 | Active, not recruiting | Sun Yat-sen University | 2026-10-20 |
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | Quizartinib | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 2026-10-07 |
| A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma) | Catequentinib | Phase 2 | Recruiting | Sun Yat-sen University | 2026-10-07 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors | Regorafenib | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-10-05 |
| First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain | Pazopanib, Sunitinib, Tivozanib | — | Active, not recruiting | Bristol-Myers Squibb | 2026-10-01 |
| An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer | Catequentinib | Not applicable | Not yet recruiting | Zhejiang Cancer Hospital | 2026-09-30 |
| Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma | Catequentinib | Phase 2 | Not yet recruiting | Fudan University | 2026-09-29 |
| Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial | Famitinib | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 2026-09-29 |
| De-escalation Strategy of Tyrosine Kinase Inhibitors Before Treatment Discontinuation in Patients With Chronic Myeloid Leukemia | Imatinib | Phase 4 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 2026-09-24 |
| Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma | Sorafenib | Phase 3 | Recruiting | BeOne Medicines | 2026-09-23 |
| Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer | Famitinib | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 2026-09-11 |
| Real-world Insight Into Systemic Therapies for HCC: Single-center Study | Sorafenib | — | Recruiting | Mansoura University | 2026-09-10 |
| Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC | Famitinib | Phase 2 | Recruiting | First Affiliated Hospital Xi'an Jiaotong University | 2026-08-31 |
| Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma | Sorafenib | Phase 2 | Recruiting | Anna Raciborska | 2026-08-26 |
| Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer | Regorafenib | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 2026-08-14 |
| A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer | Regorafenib | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-08-06 |
| A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan | Regorafenib | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 2026-07-28 |
| Hyperpolarized MRI for GIST on Imatinib | Imatinib | — | Not yet recruiting | Chang Gung Memorial Hospital | 2026-07-24 |
| Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia | Midostaurin | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Bordeaux | 2026-07-24 |
| IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer | Regorafenib | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 2026-07-23 |
| DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML | Sorafenib | Phase 3 | Recruiting | The Second Affiliated Hospital of Kunming Medical University | 2026-07-20 |
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome | Regorafenib | Phase 2 | Not yet recruiting | Xiang-Qian | 2026-07-09 |
| A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib | Imatinib, Regorafenib, Sunitinib | Phase 2 | Recruiting | GlaxoSmithKline | 2026-07-08 |
| An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer | Sunitinib | Phase 2 | Recruiting | Bai-Rong Xia | 2026-06-25 |
| Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies | Famitinib | Phase 1 / Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 2026-06-23 |
| A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions | Sorafenib | — | Active, not recruiting | Harbin Medical University | 2026-06-12 |
| Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer | Famitinib | Phase 2 | Not yet recruiting | Hunan Cancer Hospital | 2026-06-04 |
| A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) | Imatinib | Phase 3 | Recruiting | GlaxoSmithKline | 2026-05-13 |
| Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML | Midostaurin, Sorafenib | — | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2026-05-07 |
| Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors | Regorafenib | Phase 1 | Recruiting | West China Hospital | 2026-05-05 |
| SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin | Sorafenib | Phase 2 | Recruiting | National Taiwan University Hospital | 2026-05-01 |
| Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria | Imatinib | Phase 2 | Recruiting | Victoria Biomedical Research Institute | 2026-04-30 |
| A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany | Imatinib | — | Recruiting | Novartis Pharmaceuticals | 2026-04-24 |
| Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms | Motesanib | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 2026-04-24 |
| Study of SA+X in the Treatment of Newly Diagnosed AML | Quizartinib | Phase 2 | Recruiting | Ruijin Hospital | 2026-04-23 |
| Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis | Imatinib | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2026-04-15 |
| Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma | Famitinib | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 2026-04-08 |
| Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) | Quizartinib | Phase 3 | Recruiting | PETHEMA Foundation | 2026-03-18 |
| A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma | Sunitinib | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 2026-03-17 |
| A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer | Famitinib | Not applicable | Not yet recruiting | Jin LI | 2026-03-12 |
| MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib | Sorafenib | Phase 3 | Recruiting | The First Affiliated Hospital of Soochow University | 2026-03-11 |
| A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas | Pazopanib | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 2026-03-03 |
| FLT3-ITD Targeted Therapy in Fit AML Patients | Midostaurin, Quizartinib | Phase 2 / Phase 3 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 2026-02-23 |
| Imetelstat Combinations in Relapsed AML | Motesanib | Phase 1 | Recruiting | Douglas Tremblay | 2026-01-06 |
| An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM) | Avapritinib | — | Recruiting | Blueprint Medicines Corporation | 2025-12-04 |
| A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany | Avapritinib | — | Recruiting | Blueprint Medicines Corporation | 2025-12-01 |
| A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy | Sunitinib | Phase 3 | Recruiting | GlaxoSmithKline | 2025-10-21 |
| Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients | Masitinib | Phase 3 | Not yet recruiting | AB Science | 2025-09-16 |
| A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI | Sunitinib | Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | 2025-09-10 |
| MRD-positive AML Clinical Study | Avapritinib | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 2025-08-20 |
| Resistance Profiling Using Functional Imaging and Next Generation Sequencing in Refractory Gastrointestinal Stomal Tumors (GIST) | Ripretinib | — | Not yet recruiting | Universität Duisburg-Essen | 2025-08-07 |
| A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma | Pazopanib | Phase 2 | Recruiting | Imbioray (Hangzhou) Biomedicine Co., Ltd. | 2025-07-25 |
| Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma | CM-082 | Phase 2 | Active, not recruiting | Dong Wen | 2025-07-02 |
| A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia | Avapritinib | Phase 1 / Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 2025-06-19 |
| Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1) | Pazopanib | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 2025-03-26 |
| Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission | Quizartinib | Phase 2 | Recruiting | Daiichi Sankyo | 2025-02-13 |
| Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents | Pazopanib | Phase 2 | Recruiting | Shandong Cancer Hospital and Institute | 2025-02-10 |
| Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT | Avapritinib | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 2025-01-20 |
| Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia | Quizartinib | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 2025-01-10 |
| Avapritinib Maintenance for AML With KIT Mutations | Avapritinib | Phase 2 | Not yet recruiting | Ruijin Hospital | 2025-01-09 |
| Avapritinib Rollover Study | Avapritinib | Phase 4 | Recruiting | Blueprint Medicines Corporation | 2024-12-24 |
| Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion | Pazopanib | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 2024-12-18 |
| Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment | Quizartinib | Phase 1 | Recruiting | Daiichi Sankyo | 2024-12-18 |
| Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study) | Pazopanib | Phase 3 | Recruiting | Sun Yat-sen University | 2024-12-10 |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | Tivozanib | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 2024-10-28 |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | Quizartinib | Phase 3 | Active, not recruiting | Daiichi Sankyo | 2024-08-29 |
| Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients | CM-082 | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-08-29 |
| Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST | Ripretinib | Not applicable | Recruiting | First Affiliated Hospital of Chongqing Medical University | 2024-07-18 |
| Avapritinib With Decitabine in Patients With SM-AHN | Avapritinib | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 2024-03-25 |
| Revumenib in Combination With 7+3 + Midostaurin in AML | Midostaurin | Phase 1 | Recruiting | Richard Stone, MD | 2024-03-15 |
| Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) | Seralutinib | Phase 3 | Recruiting | Gossamer Bio USA, Inc. | 2024-02-23 |
| A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) | Pazopanib | Phase 3 | Recruiting | Intensity Therapeutics, Inc. | 2024-02-16 |
| Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients | Midostaurin | Phase 1 | Recruiting | University Hospital Tuebingen | 2024-02-09 |
| A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy | Motesanib | Phase 1 | Recruiting | Children's Oncology Group | 2024-02-08 |
| Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function | Briquilimab | Phase 1 / Phase 2 | Active, not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 2023-11-24 |
| Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma | Tivozanib | Phase 2 | Active, not recruiting | M.D. Anderson Cancer Center | 2023-09-26 |
| A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | Ripretinib | Phase 1 / Phase 2 | Active, not recruiting | Deciphera Pharmaceuticals, LLC | 2023-07-24 |
| Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency | Briquilimab | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | 2023-06-18 |
| A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib | Ripretinib | Phase 3 | Active, not recruiting | Deciphera Pharmaceuticals, LLC | 2023-02-17 |
| Drug Screening Using Novel IMD in Renal Cell Carcinoma | Tivozanib | Phase 1 | Recruiting | Oliver Jonas | 2023-01-26 |
| Masitinib in Patients With Mild Alzheimer's Disease | Masitinib | Phase 3 | Not yet recruiting | AB Science | 2022-10-03 |
| A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors | Tivozanib | Phase 1 | Recruiting | Arcus Biosciences, Inc. | 2022-09-10 |
| First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | Ripretinib | Phase 1 | Active, not recruiting | IDRX, Inc., a wholly owned subsidiary of GSK, LLC | 2022-08-05 |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | Motesanib | Phase 1 | Active, not recruiting | Geron Corporation | 2022-05-12 |
| Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia | Briquilimab | Phase 1 / Phase 2 | Active, not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 2022-05-03 |
| Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | Tivozanib | Phase 1 / Phase 2 | Recruiting | University of Florida | 2021-08-11 |
| Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab | Briquilimab | Phase 1 / Phase 2 | Recruiting | Porteus, Matthew, MD | 2021-03-05 |
| Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML) | Midostaurin | — | Recruiting | Acute Leukemia French Association | 2021-03-02 |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | Cediranib | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | 2021-02-05 |
| TDM for Optimized Outcome in Patients With mRCC. | Tivozanib | — | Recruiting | Niels Fristrup | 2020-12-09 |
| Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers | Tivozanib | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 2020-11-27 |
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment | Motesanib | Phase 3 | Active, not recruiting | Geron Corporation | 2020-10-06 |
| A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT | Pexidartinib | Phase 3 | Active, not recruiting | Daiichi Sankyo Co., Ltd. | 2020-07-28 |
| A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer | Cediranib | Phase 2 | Active, not recruiting | The Clatterbridge Cancer Centre NHS Foundation Trust | 2020-07-27 |
| Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) | Midostaurin | Phase 1 / Phase 2 | Recruiting | Technische Universität Dresden | 2020-05-12 |
| Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients | Midostaurin | Phase 2 | Active, not recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2019-09-20 |
| Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer | Cediranib | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 2019-09-16 |
| Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors | Cediranib | Phase 2 | Active, not recruiting | University Health Network, Toronto | 2019-02-22 |
| WIRE - Novel Treatments in Renal Cell Cancer | Cediranib | Phase 2 | Recruiting | CCTU- Cancer Theme | 2018-11-14 |
| A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Ripretinib | Phase 3 | Active, not recruiting | Deciphera Pharmaceuticals, LLC | 2018-09-17 |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone | Cediranib | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | 2018-09-07 |
| Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy | Cediranib | Phase 2 | Active, not recruiting | AstraZeneca | 2017-11-07 |
| Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients | Masitinib | Phase 3 | Recruiting | AB Science | 2017-04-25 |
| Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma | Cediranib | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | 2016-11-28 |
| Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | Motesanib | Phase 2 / Phase 3 | Active, not recruiting | Geron Corporation | 2015-11-06 |
| Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... | Pexidartinib | Phase 1 | Recruiting | National Cancer Institute (NCI) | 2015-03-18 |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Pexidartinib | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 2010-01-05 |